Treatment of Primary Ovarian Lymphoma in Diffuse Large B-Cell Lymphoma, Stage III–IV
Primary ovarian lymphoma presenting as diffuse large B-cell lymphoma (DLBCL) at advanced stage III–IV is a specific clinical scenario with a defined evidence-based treatment pathway.
Clinical Scenario
This protocol addresses primary ovarian lymphoma of the diffuse large B-cell lymphoma subtype at advanced stage III or IV. The DLBCL subtype at this stage is the defining characteristic shaping the management approach.
Treatment Approach
Management of relapsed or refractory disease involves targeted immunotherapy approaches, with agent selection guided by the timing of disease progression and the number of prior treatment lines. The complete evidence-based algorithm is available in the full protocol.
References
DOI: 10.1016/j.annonc.2025.07.014
- Axicabtagene ciloleucel [I, A].
- Lisocabtagene maraleucel [I, A].
- Glofitamab-Gem-Ox (after one or more line of therapy) [I, A; EMA approved, not FDA approved].
- Pola-BR if polatuzumab naive [II, B].
- Tafasitamab—lenalidomide [III, B].
- R-Gem-Ox [III, C].
- Patients relapsing after two or more prior lines of treatment should receive CAR-T therapy, if suitable [III, A].
- Tisagenlecleucel [III, A].
- Glofitamab-Gem-Ox [I, A; EMA approved, not FDA approved] or glofitamab alone [III, A] if bispecific antibody naive.
- Epcoritamab if bispecific antibody naive [III, A].
- Odronextamab if bispecific antibody naive [III, A; EMA approved, not FDA approved].
- Loncastuximab—tesirine [III, B].
View source ↗